Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74:229–263

Article  PubMed  Google Scholar 

Siegel RL, Giaquinto AN, Jemal A (2024) Cancer statistics, 2024. CA Cancer J Clin 74:12–49

Article  PubMed  Google Scholar 

Armitage JO, Gascoyne RD, Lunning MA, Cavalli F (2017) Non-hodgkin lymphoma. Lancet 390:298–310

Article  PubMed  Google Scholar 

Huang J, Chan SC, Lok V, Zhang L, Lucero-Prisno DE 3rd, Xu W, Zheng ZJ, Elcarte E, Withers M, Wong MCS (2024) Global burden, risk factors, and trends of non-Hodgkin lymphoma: A worldwide analysis of cancer registries. Cancer Med 13:e7056

Article  PubMed  PubMed Central  Google Scholar 

Mlynarczyk C, Fontan L, Melnick A (2019) Germinal center-derived lymphomas: The darkest side of humoral immunity. Immunol Rev 288:214–239

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu Y, Li Y, Zhang C, Yang X, Yang B, Cheng J, Chen J, Yuan X, Li Y, Chen Y, Zhang F, Tang D, He Z, Wang F (2024) Efficacy and safety of lenalidomide in the treatment of B-cell non-Hodgkin lymphoma. Discov Oncol 15:105

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xu PP, Huo YJ, Zhao WL (2022) All roads lead to targeted diffuse large B-cell lymphoma approaches. Cancer Cell 40:131–133

Article  CAS  PubMed  Google Scholar 

Gordon MJ, Smith MR, Nastoupil LJ (2023) Follicular lymphoma: The long and winding road leading to your cure? Blood Rev 57:100992

Article  PubMed  Google Scholar 

Zheng W, Liu M, Guan L, Wang S (2024) Outcomes of the transformation of follicular lymphoma to diffuse large B-cell lymphoma in the rituximab era: A population-based study. Cancer Med 13:e7120

Article  CAS  PubMed  PubMed Central  Google Scholar 

Casulo C, Friedberg JW (2018) Burkitt lymphoma- a rare but challenging lymphoma. Best Pract Res Clin Haematol 31:279–284

Article  PubMed  Google Scholar 

Ansell SM (2015) Non-hodgkin lymphoma: diagnosis and treatment. Mayo Clin Proc 90:1152–1163

Article  PubMed  Google Scholar 

Jardin F, Ruminy P, Bastard C, Tilly H (2007) The BCL6 proto-oncogene: a leading role during germinal center development and lymphomagenesis. Pathol Biol (Paris) 55:73–83

Article  CAS  PubMed  Google Scholar 

Ohno H (2004) Pathogenetic role of BCL6 translocation in B-cell non-Hodgkin’s lymphoma. Histol Histopathol 19:637–650

CAS  PubMed  Google Scholar 

Ye BH, Lista F, Lo Coco F, Knowles DM, Offit K, Chaganti RS, Dalla-Favera R (1993) Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma. Science 262:747–750

Article  CAS  PubMed  Google Scholar 

Hatzi K, Melnick A (2014) Breaking bad in the germinal center: how deregulation of BCL6 contributes to lymphomagenesis. Trends Mol Med 20:343–352

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pasqualucci L (2023) The germinal center in the pathogenesis of B cell lymphomas. Hematol Oncol 41(Suppl 1):62–69

Article  PubMed  Google Scholar 

Basso K, Dalla-Favera R (2015) Germinal centres and B cell lymphomagenesis. Nat Rev Immunol 15:172–184

Article  CAS  PubMed  Google Scholar 

Huang C, Melnick A (2015) Mechanisms of action of BCL6 during germinal center B cell development. Sci China Life Sci 58:1226–1232

Article  CAS  PubMed  Google Scholar 

Cerchietti L, Melnick A (2013) Targeting BCL6 in diffuse large B-cell lymphoma: what does this mean for the future treatment? Expert Rev Hematol 6:343–345

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cardenas MG, Oswald E, Yu W, Xue F, MacKerell AD Jr, Melnick AM (2017) The expanding role of the bcl6 oncoprotein as a cancer therapeutic target. Clin Cancer Res 23:885–893

Article  CAS  PubMed  Google Scholar 

Huynh KD, Bardwell VJ (1998) The BCL-6 POZ domain and other POZ domains interact with the co-repressors N-CoR and SMRT. Oncogene 17:2473–2484

Article  CAS  PubMed  Google Scholar 

Huang C, Hatzi K, Melnick A (2013) Lineage-specific functions of Bcl-6 in immunity and inflammation are mediated by distinct biochemical mechanisms. Nat Immunol 14:380–388

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ye BH, Cattoretti G, Shen Q, Zhang J, Hawe N, de Waard R, Leung C, Nouri-Shirazi M, Orazi A, Chaganti RS, Rothman P, Stall AM, Pandolfi PP, Dalla-Favera R (1997) The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation. Nat Genet 16:161–170

Article  CAS  PubMed  Google Scholar 

Polo JM, Dell’Oso T, Ranuncolo SM, Cerchietti L, Beck D, Da Silva GF, Prive GG, Licht JD, Melnick A (2004) Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. Nat Med 10:1329–1335

Article  CAS  PubMed  Google Scholar 

Cerchietti LC, Yang SN, Shaknovich R, Hatzi K, Polo JM, Chadburn A, Dowdy SF, Melnick A (2009) A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo. Blood 113:3397–3405

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cerchietti LC, Ghetu AF, Zhu X, Da Silva GF, Zhong S, Matthews M, Bunting KL, Polo JM, Fares C, Arrowsmith CH et al (2010) A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. Cancer Cell 17:400–411

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cardenas MG, Yu W, Beguelin W, Teater MR, Geng H, Goldstein RL, Oswald E, Hatzi K, Yang SN, Cohen J et al (2016) Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma. J Clin Invest 126:3351–3362

Article  PubMed  PubMed Central  Google Scholar 

Kerres N, Steurer S, Schlager S, Bader G, Berger H, Caligiuri M, Dank C, Engen JR, Ettmayer P, Fischerauer B et al (2017) Chemically induced degradation of the oncogenic transcription factor BCL6. Cell Rep 20:2860–2875

Article  CAS  PubMed  Google Scholar 

Almatroodi SA, Alsahli MA, Aljohani SMA, Alhumaydhi FA, Babiker AY, Rahmani KAA, AH, (2022) Potential therapeutic targets of resveratrol, a plant polyphenol, and its role in the therapy of various types of cancer. Molecules 27:2665

Article  CAS  PubMed  PubMed Central  Google Scholar 

Faber AC, Chiles TC (2006) Resveratrol induces apoptosis in transformed follicular lymphoma OCI-LY8 cells: evidence for a novel mechanism involving inhibition of BCL6 signaling. Int J Oncol 29:1561–1566

CAS  PubMed  Google Scholar 

Ranuncolo SM, Polo JM, Dierov J, Singer M, Kuo T, Greally J, Green R, Carroll M, Melnick A (2007) Bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR. Nat Immunol 8:705–714

Article  CAS  PubMed